Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline <i>BRCA</i>-associated breast cancer (SWOG S1416).
Priyanka Sharma(Chandigarh University), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center), Thu-Tam Huynh(Kaiser Permanente Anaheim Medical Center), Harsh B. Pathak(University of Kansas Medical Center), Lajos Pusztai(Yale University), Julie R. Gralow(American Society of Clinical Oncology), Andrew K. Godwin(The University of Melbourne), Kirsten M. Timms(Myriad (Germany)), Ursa Brown‐Glaberman(University of New Mexico), Shannon Leigh Huggins-Puhalla(UPMC Hillman Cancer Center), Christopher Scott Szyarto(Michigan Cancer Research Consortium), Lori J. Goldstein(Shaanxi Research Association for Women and Family), Eve T. Rodler(UC Davis Comprehensive Cancer Center), Marc R. Radke(University of Washington), Daniel F. Hayes(University of Michigan–Ann Arbor), William E. Barlow(Cancer Research And Biostatistics), Elizabeth M. Swisher(University of Washington), Danika L. Lew, Jieling Miao, Carey K. Anders(Duke University)
Cited by 49
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Current and future burden of breast cancer: Global statistics for 2020 and 2040
|The Breast|2022|3.3k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k